Clinical trial
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III…
NCT00004198 · University of Nebraska, Other · Completed
Key facts
| NCT number | NCT00004198 |
|---|---|
| Title | Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma |
| Official title | A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Indolent B Cell Lymphoma |
| Lead sponsor | University of Nebraska, Other |
| Collaborators | National Cancer Institute (NCI) NIH Genitope Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | keyhole limpet hemocyanin, sargramostim, tumor cell-based vaccine therapy |
| Start date | Jun 25, 1999 |
| Primary completion | Jan 1, 2002 |
| Completion | Nov 20, 2003 |
| First posted | May 21, 2004 |
| Last update posted | Dec 27, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: